Status:

UNKNOWN

AN OPEN-LABEL, ACUTE CLINICAL TRIAL TO ASSESS THE LEVEL OF KETONE PRODUCTION FOLLOWING CONSUMPTION OF AVELA™ (R)-1,3-BUTANEDIOL IN AN ADULT POPULATION

Lead Sponsor:

Genomatica Inc.

Conditions:

Healthy

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The purpose of the pilot clinical trial described herein is to determine the level of ketone production \[measured as β hydroxybutyrate (BHB)\] following consumption of (R)-1,3-butanediol in a beverag...

Detailed Description

Primary: To evaluate the level of production of BHB following the consumption of 3 servings of Avela™, with consumption of each serving separated by 30 minutes and each serving providing 11.5 g of (R...

Eligibility Criteria

Inclusion

  • Males and females, 18 to 65 years of age
  • BMI 18 to \<35.0 kg/m2, inclusive
  • Weight ≥ 110 lbs
  • Subject is judged to be in good health on the basis of medical history
  • Subject is willing to fast for 12 hours prior to study start
  • Subject is willing to avoid alcohol and intense physical activity the day prior to and on the day of testing
  • Subject is capable of giving informed consent and complying with all study procedures/requirements.

Exclusion

  • Previous GI disorders (e.g., inflammatory bowel disease, irritable bowel syndrome, history of surgery for weight loss, or gastroparesis)
  • Gastroenteritis in the 2 weeks preceding the study
  • Diabetes
  • Weight \<110 lbs
  • History of alcohol or drug abuse
  • Previous diagnosis of neurological disorders, depression, or mental illness with psychosis
  • Unexplained alarm features (i.e., unintentional weight loss \>10% body weight in the last 3 months, fevers, or blood in stools)
  • Use of an antibiotic or any medication impacting gut transit during the 2 weeks before the study
  • Constipation or diarrhea (defined as, on average, less than 3 stools per week or more than 3 stools per day, respectively)
  • Allergy to tree nuts
  • Women who are pregnant or breastfeeding
  • Persons with medical conditions affecting the pancreas, liver, thyroid, or gall bladder.

Key Trial Info

Start Date :

May 25 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2022

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT05384106

Start Date

May 25 2022

End Date

June 30 2022

Last Update

May 20 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Moniker Commons

San Diego, California, United States, 92106